Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Consensus Target Price from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $16.00.

COYA has been the topic of several analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Friday, April 10th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, March 23rd. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Monday, April 20th. Finally, Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th.

Coya Therapeutics Stock Performance

Shares of Coya Therapeutics stock opened at $4.96 on Wednesday. The firm has a market cap of $116.36 million, a P/E ratio of -4.31 and a beta of 0.55. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75. The stock’s fifty day moving average price is $4.38 and its 200-day moving average price is $5.03.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%.The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. Analysts forecast that Coya Therapeutics will post -1.5 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of large investors have recently bought and sold shares of the company. Prosperity Wealth Management Inc. boosted its position in Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Coya Therapeutics in the third quarter valued at approximately $28,000. Cetera Investment Advisers boosted its position in Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares during the last quarter. CIBC Private Wealth Group LLC purchased a new stake in Coya Therapeutics in the fourth quarter valued at approximately $47,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in Coya Therapeutics in the fourth quarter valued at approximately $66,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.